In summary, we demonstrated that molecular analysis of cfDNA for selected oncogenic mutations in BRAF, EGFR, KRAS, and PIK3CA is feasible and demonstrates acceptable concordance with standard of care mutation testing of archival tumor tissue and that the amount of mutant cfDNA is an independent prognostic factor for survival. This evidence concerns the gene KRAS and neoplasm.